BIOreACT – Goodbye Flattened Biology

BIOreACT aims at providing advanced physical platforms for more accurate ex vivo 3D cell-based assays and diagnostics for Pharma and Cosmetic Industries. BIOreACT offers to the market a specialized dual-chamber system as a solution for the problematic inefficiency of in vitro drug screening, which nowadays relies mainly on 2D platforms or non-mimetic 3D approaches, which are not designed for interfaced tissues. Naturally, our body is composed of a set of tissues interfacing each other by direct contact, which not only constitute physical barriers for drugs to pass but are also affected by disorders involving two different adjacent tissues. Currently, Pharma and Cosmetic Industries have no solutions for this specific need. BIOreACT technology has been tested to create hierarchical-neural phenotypes, bone-cartilage interface, heterogeneous cancer models and layered-skin surrogates. Unlike the current technologies, BIOreACT offers a ready-to-use platform for robust control over representative human-like models for drug and cosmetics screening.